Atumelnant

Phase 3Small molecule

CCrinetics Pharmaceuticals Inc.

Atumelnant is one of 8 small molecule programs targeting Congenital Adrenal Hyperplasia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Congenital Adrenal HyperplasiaRecruiting

Cushing SyndromeActive, not recruiting

Congenital Adrenal HyperplasiaPhase 3

Recruiting

Cushing SyndromePreclinical

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Congenital Adrenal Hyperplasia

#DrugCompanyPhaseTrials

Crenessity

Neurocrine Biosciences

Phase 3

5 2

Lu AF95245

Lundbeck

Phase 2

1 3

Atumelnant

CCrinetics Pharmaceuticals Inc.

Phase 3

4 4

Actos

Takeda

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalActive, not recruiting

Cushing Syndrome

NCT05804669

Q2 2027

Phase 3Recruiting

Congenital Adrenal Hyperplasia

NCT07144163

Q3 2029

Phase 2Recruiting

Congenital Adrenal Hyperplasia

NCT06712823

Q1 2030

PreclinicalRecruiting

Congenital Adrenal Hyperplasia

NCT07159841

Clinical

Trials by Indication[1]

Congenital Adrenal Hyperplasia4 trials

A 12-week, Phase 2 Open-label, Sequential Dose Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 Treatment in Participants With Congenital Adrenal Hyperplasia (TouCAHn)

Completed·CCrinetics Pharmaceuticals Inc.·Phase 2·NCT05907291·38 enrolled

A Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Atumelnant Treatment in Pediatric Participants With Congenital Adrenal Hyperplasia Including a Long-Term Extension

Recruiting·CCrinetics Pharmaceuticals Inc.·Preclinical·NCT07159841·153 enrolled

A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atumelnant in Adult Participants With Classic Congenital Adrenal Hyperplasia (Calm-CAH)

Recruiting·CCrinetics Pharmaceuticals Inc.·Phase 3·NCT07144163·150 enrolled

Show 1 more trial

An Open-label, Long-term Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal Hyperplasia (CALM2-CAH)

Recruiting·CCrinetics Pharmaceuticals Inc.·Phase 2·NCT06712823·200 enrolled

Tics1 trial

A Study to Assess Pharmacokinetics, Safety, and Tolerability of Atumelnant in Healthy Japanese and Caucasian Participants

Completed·CCrinetics Pharmaceuticals Inc.·Phase 1·NCT07221084·21 enrolled

Cushing syndrome1 trial

A Phase 1b/2a Open-label Multiple-ascending Dose Exploratory Study of CRN04894 in ACTH-dependent Cushing's Syndrome (Cushing's Disease or Ectopic ACTH Syndrome)

Active, not recruiting·CCrinetics Pharmaceuticals Inc.·Preclinical·NCT05804669·19 enrolled

Unspecified1 trial

A Phase 1, Open-Label, Two-Cohort Study to Assess the Effect of a Strong CYP3A4 Inducer on the Pharmacokinetics of Atumelnant and the Effect of Atumelnant on the Pharmacokinetics of CYP3A4, P-gp, and MATE1/2-K Substrates in Healthy Participants

Completed·CCrinetics Pharmaceuticals Inc.·Phase 1·NCT07570082·46 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Atumelnant. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Atumelnant compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Atumelnant. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Crinetics Pharmaceuticals Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCrinetics Pharmaceuticals Inc.

Atumelnant

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q3 2029

Q1 2030

Trials by Indication[1]

Congenital Adrenal Hyperplasia4 trials

Tics1 trial

Cushing syndrome1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News